PF-08653944
Medium EvidenceAn ultra-long-acting injectable GLP-1 receptor agonist enabling monthly dosing, with 12.3% placebo-adjusted weight loss in Phase 2b and 10 Phase 3 trials planned.
What It Is
PF-08653944 (also known as MET-097i or PF'3944) is a fully-biased, ultra-long-acting injectable GLP-1 receptor agonist being developed by Pfizer, acquired through its $10 billion purchase of Metsera. What distinguishes PF'3944 from existing GLP-1 drugs is its pharmacokinetic profile enabling once-monthly maintenance dosing after an initial weekly titration period. In the Phase 2b VESPER-3 trial, PF'3944 demonstrated up to 12.3% mean placebo-adjusted weight loss at 28 weeks in adults with obesity or overweight without type 2 diabetes. Weight loss continued after switching from weekly to monthly dosing with no plateau observed at 28 weeks, and the safety profile was well-tolerated and consistent with the GLP-1 RA class. Pfizer plans 10 Phase 3 trials of PF'3944 beginning in 2026, including VESPER-4 (weekly dosing in obesity), VESPER-5 (weekly with T2D), VESPER-6 (monthly dosing in obesity), and at least seven additional studies. Detailed VESPER-3 results will be presented at the American Diabetes Association 86th Scientific Sessions on June 6, 2026. With 10 Phase 3 trials expected to advance in 2026, PF'3944 is central to Pfizer's strategy to challenge the Lilly/Novo duopoly in the obesity market — analysts position it as a potential top-3 monthly dosing contender alongside MariTide and the Ascletis pipeline.
Regulatory Status
Phase 2b VESPER-3 completed. Phase 3 VESPER-4 (weekly dosing, obesity without T2D) initiated. 10 Phase 3 trials planned including VESPER-5 (weekly with T2D) and VESPER-6 (monthly dosing).
Effective: February 2026
View FDA SourceWhy Researchers Study It
PF'3944's ability to deliver clinically meaningful weight loss with once-monthly dosing could dramatically improve adherence and convenience compared to weekly injections. If Phase 3 confirms Phase 2b results, it would be the first monthly GLP-1 option, potentially reshaping the competitive landscape alongside oral formulations like orforglipron.
Proposed Mechanisms
- Full GLP-1 receptor agonism with biased signaling profile
- Ultra-long pharmacokinetic half-life enables monthly dosing
- Central appetite suppression via hypothalamic GLP-1 receptors
- Slowed gastric emptying contributing to reduced food intake
- Potential cardiovascular and metabolic benefits consistent with GLP-1 class
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Phase 2b (VESPER-3) | 28-week, weekly-to-monthly transition, obesity without T2D | Up to 12.3% placebo-adjusted weight loss; continued loss after switch to monthly; no plateau at 28 weeks | Source |
Commonly Discussed Benefits
Researching PF-08653944? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Phase 3 VESPER-4 trial initiated; 10 Phase 3 trials planned across weekly and monthly dosing regimens
- 28-week data — longer-term efficacy and safety unknown
- GI side effects (nausea, vomiting) consistent with GLP-1 class
- Monthly dosing convenience must be weighed against injection-site considerations
- No regulatory submissions yet
Comparisons
See how PF-08653944 compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
Keep researching in the app
- Log PF-08653944 to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Tirzepatide
High EvidenceA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.
Semaglutide
High EvidenceA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.
Orforglipron
High EvidenceThe first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions.
Retatrutide
High EvidenceAn investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease.
Survodutide
Medium EvidenceA dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026.